| Drug Name |
Toremifene citrate |
| Drug ID |
BADD_D02250 |
| Description |
A first generation nonsteroidal selective estrogen receptor modulator (SERM) that is structurally related to tamoxifen. Like tamoxifen, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue. |
| Indications and Usage |
For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer. |
| Marketing Status |
approved; investigational |
| ATC Code |
L02BA02 |
| DrugBank ID |
DB00539
|
| KEGG ID |
D00967
|
| MeSH ID |
D017312
|
| PubChem ID |
3005572
|
| TTD Drug ID |
D04VFJ
|
| NDC Product Code |
64980-404; 17337-0305; 90027-020; 73377-183; 72205-050; 52483-0060; 73309-291; 42747-327; 69539-152; 54893-0079 |
| UNII |
2498Y783QT
|
| Synonyms |
Toremifene | Toremifene, (E)-Isomer | Toremifene Citrate | Citrate, Toremifene | Toremifene Citrate (1:1) | Fareston | FC-1157a | FC 1157a | FC1157a |
